Zacks: Brokerages Expect Meridian Bioscience, Inc. (VIVO) Will Post Earnings of $0.20 Per Share

Wall Street brokerages expect Meridian Bioscience, Inc. (NASDAQ:VIVO) to post $0.20 earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have issued estimates for Meridian Bioscience’s earnings, with the lowest EPS estimate coming in at $0.19 and the highest estimate coming in at $0.21. Meridian Bioscience posted earnings per share of $0.22 in the same quarter last year, which would indicate a negative year over year growth rate of 9.1%. The business is expected to issue its next earnings results on Thursday, April 26th.

According to Zacks, analysts expect that Meridian Bioscience will report full year earnings of $0.71 per share for the current fiscal year, with EPS estimates ranging from $0.67 to $0.76. For the next financial year, analysts forecast that the business will report earnings of $0.77 per share, with EPS estimates ranging from $0.73 to $0.81. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Meridian Bioscience.

Meridian Bioscience (NASDAQ:VIVO) last issued its quarterly earnings data on Thursday, January 25th. The company reported $0.15 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.14 by $0.01. Meridian Bioscience had a return on equity of 17.00% and a net margin of 10.46%. The company had revenue of $52.30 million during the quarter, compared to analyst estimates of $49.00 million. During the same quarter in the previous year, the firm earned $0.15 earnings per share. Meridian Bioscience’s revenue was up 11.8% on a year-over-year basis.

VIVO has been the subject of several recent analyst reports. Canaccord Genuity boosted their price objective on Meridian Bioscience from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Friday, January 26th. Zacks Investment Research lowered Meridian Bioscience from a “buy” rating to a “hold” rating in a report on Sunday, January 21st. Finally, BidaskClub lowered Meridian Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, February 3rd.

Shares of Meridian Bioscience (VIVO) traded down $0.05 during midday trading on Monday, hitting $14.50. The stock had a trading volume of 204,139 shares, compared to its average volume of 318,254. Meridian Bioscience has a 52 week low of $12.45 and a 52 week high of $16.45. The company has a quick ratio of 3.96, a current ratio of 5.82 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $615.58, a price-to-earnings ratio of 21.40 and a beta of 0.98.

The company also recently announced a quarterly dividend, which was paid on Thursday, February 15th. Shareholders of record on Monday, February 5th were paid a $0.125 dividend. This represents a $0.50 annualized dividend and a yield of 3.45%. The ex-dividend date of this dividend was Friday, February 2nd. Meridian Bioscience’s dividend payout ratio is currently 98.04%.

A number of institutional investors and hedge funds have recently modified their holdings of the business. MetLife Investment Advisors LLC purchased a new stake in Meridian Bioscience in the fourth quarter worth approximately $316,000. Vident Investment Advisory LLC purchased a new stake in Meridian Bioscience in the fourth quarter worth approximately $217,000. Jane Street Group LLC purchased a new stake in Meridian Bioscience in the fourth quarter worth approximately $140,000. Millennium Management LLC boosted its stake in Meridian Bioscience by 55.0% in the fourth quarter. Millennium Management LLC now owns 1,133,765 shares of the company’s stock worth $15,873,000 after buying an additional 402,430 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. boosted its stake in Meridian Bioscience by 642.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 19,300 shares of the company’s stock worth $270,000 after buying an additional 16,700 shares in the last quarter. 85.37% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This article was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/17/zacks-brokerages-expect-meridian-bioscience-inc-vivo-will-post-earnings-of-0-20-per-share.html.

Meridian Bioscience Company Profile

Meridian Bioscience, Inc is a life science company engaged in the development, manufacture, sale and distribution of diagnostic test kits for gastrointestinal, viral, respiratory and parasitic infectious diseases, and elevated blood lead levels, and the manufacture and distribution of bulk antigens, antibodies, polymerase chain reaction (PCR)/quantitative PCR (qPCR) reagents, nucleotides, competent cells and bioresearch reagents used by researchers and other diagnostic manufacturers.

Get a free copy of the Zacks research report on Meridian Bioscience (VIVO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply